Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.

Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.

Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.